亚日韩在线中文字幕亚洲,国产在线播放鲁啊鲁视频,张柏芝手扒性器全部图片,亚洲成无码电影在线观看

　　細(xì)胞名稱(chēng)：人子宮內(nèi)膜癌細(xì)胞USPC-ARK-2

產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2

細(xì)胞數(shù)量：1x10^6；1x10^6

保存溫度：37℃；-198℃

運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸

安全等級(jí)：1

用途限制：僅供科研2類(lèi)

培養(yǎng)體系：MEM高糖培養(yǎng)基+10%FBS+1%雙抗

培養(yǎng)溫度：37℃

二氧化碳濃度：5%

簡(jiǎn)介：人子宮內(nèi)膜癌細(xì)胞USPC-ARK-2取自63歲女性供體，貼壁培養(yǎng)。

注釋?zhuān)篍ndometrial serous adenocarcinoma

基因突變：/

HLA信息：/

STR信息：/

參考文獻(xiàn)

PubMed=19920829;DOI=10.1038/sj.bjc.6605448

El-Sahwi K.,Bellone S.,Cocco E.,Cargnelutti M.,Casagrande F.,Bellone M.,Abu-Khalaf M.,Buza N.,Tavassoli F.A.,Hui P.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Rutherford T.J.,Pecorelli S.,Santin A.D.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.

Br.J.Cancer 102:134-143(2010)

PubMed=21246534;DOI=10.1002/cncr.25891

Varughese J.,Cocco E.,Bellone S.,de Leon M.,Bellone M.,Todeschini P.,Schwartz P.E.,Rutherford T.J.,Pecorelli S.,Santin A.D.

Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker(Trop-2)and are highly sensitive to immunotherapy with hRS7,a humanized anti-Trop-2 monoclonal antibody.

Cancer 117:3163-3172(2011)

PubMed=23891627;DOI=10.1016/j.ajog.2013.07.020

English D.P.,Bellone S.,Cocco E.,Bortolomai I.,Pecorelli S.,Lopez S.,Silasi D.-A.,Schwartz P.E.,Rutherford T.,Santin A.D.

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980,a selective inhibitor of Class I PI3 kinase and mTOR kinase(TORC1/2).

Am.J.Obstet.Gynecol.209:465.e1-465.e9(2013)

PubMed=25268372;DOI=10.1038/bjc.2014.519

Schwab C.L.,Bellone S.,English D.P.,Roque D.M.,Lopez S.,Cocco E.,Nicoletti R.,Bortolomai I.,Bonazzoli E.,Ratner E.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Rutherford T.J.,Santin A.D.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

Br.J.Cancer 111:1750-1756(2014)

PubMed=26325104;DOI=10.1038/bjc.2015.306

Black J.D.,Lopez S.,Cocco E.,Bellone S.,Altwerger G.,Schwab C.L.,English D.P.,Bonazzoli E.,Predolini F.,Ferrari F.,Ratner E.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Santin A.D.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Br.J.Cancer 113:1020-1026(2015)

PubMed=26625219;DOI=10.1038/bjc.2015.388

Black J.D.,Lopez S.,Cocco E.,Bellone S.,Altwerger G.,Schwab C.L.,English D.P.,Bonazzoli E.,Predolini F.,Ferrari F.,Ratner E.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Santin A.D.

Erratum to:PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Br.J.Cancer 113:1641-1641(2015)

PubMed=27894751;DOI=10.1016/j.ygyno.2016.11.023

Bellone S.,Bignotti E.,Lonardi S.,Ferrari F.,Centritto F.,Masserdotti A.,Pettinella F.,Black J.,Menderes G.,Altwerger G.,Hui P.,Lopez S.,de Haydu C.,Bonazzoli E.,Predolini F.,Zammataro L.,Cocco E.,Ferrari F.,Ravaggi A.,Romani C.,Facchetti F.,Sartori E.,Odicino F.E.,Silasi D.A.,Litkouhi B.,Ratner E.,Azodi M.,Schwartz P.E.,Santin A.D.

Polymerase epsilon(POLE)ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

Gynecol.Oncol.144:146-152(2017)